Peg-amino acid-oligopeptide-irinotecan drug conjugates and the pharmaceutical compositions

A PEG-oligopeptide-irinotecan conjugate of formula (I):

• wherein:
• PEG represents polyethylene glycol with a molecular weight of 300-60,000 Daltons;
• (AA)i represents an oligopeptide, and AA represents a same or different amino acids of said oligopeptide;
• and
• i and j can be identical or different, i is an integer of 2-12 representing a number of said amino acids of said oligopeptide, and j is an integer of 2-12 representing a number of irinotecan connected with said oligopeptide.

A pharmaceutical composition, comprising:

• a PEG-oligopeptide-irinotecan conjugate of formula (I):
• wherein:
• PEG represents polyethylene glycol with a molecular weight of 300-60,000 Daltons;
• (AA)i represents an oligopeptide, and AA represents a same or different amino acids of said oligopeptide;
• i and j can be identical or different, i is an integer of 2-12 representing a number of said amino acids of said oligopeptide, and j is an integer of 2-12 representing a number of irinotecan connected with said oligopeptide;
• and
• a pharmaceutically acceptable carrier or excipient.